NCT03340649

Brief Summary

To observe the changes of plasma hepatocyte growth factor and soluble receptor s-Met levels in patients with sepsis, and to explore its clinical significance.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2017

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 8, 2017

Completed
1 day until next milestone

Study Start

First participant enrolled

November 9, 2017

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 9, 2017

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 13, 2017

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2018

Completed
Last Updated

November 13, 2017

Status Verified

November 1, 2017

Enrollment Period

Same day

First QC Date

November 8, 2017

Last Update Submit

November 9, 2017

Conditions

Sepsis

Outcome Measures

Primary Outcomes (1)

  • mortality

    28-day mortality

    28-day

Interventions

taking peripheral bloodOTHER

taking peripheral blood of no more than 3ml

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

sepsis patients

You may qualify if:

  • Patients admitted to ICU diagnosed of sepsis(sepsis3.0 criteria)
  • Patients signing informed consent

You may not qualify if:

  • Age is less than 18 years old or more than 80 years old
  • Pregnant women
  • Patients with tumor、hepatitis、liver cirrhosis、acute myocardial infarction、chronic renal tubular nephritis、interstitial pneumonia、acute pancreatitis、systemic lupus erythenatosus、ulcerative colitis、crohn's disease、HELLP syndrome
  • Prothrombin time is extension in patients with after liver transplantation
  • Patients with chronic renal failure
  • Patients after kidney transplantation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhongda Hospital

Nanjing, Jiangsu, 210000, China

RECRUITING

MeSH Terms

Conditions

Sepsis

Condition Hierarchy (Ancestors)

InfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • yi yang, doctor

    Zhongda Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

chenglong liang, master

CONTACT

1526189356215261893562@163.com

yi yang, doctor

CONTACT

+8602583262550yiyiyang2004@163.com

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Attending doctor

Study Record Dates

First Submitted

November 8, 2017

First Posted

November 13, 2017

Study Start

November 9, 2017

Primary Completion

November 9, 2017

Study Completion

March 1, 2018

Last Updated

November 13, 2017

Record last verified: 2017-11

Data Sharing

IPD Sharing
Will not share

no share IPD

Locations

CN(1)